State Street Corp Boosts Stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)

State Street Corp increased its position in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 13.2% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 279,513 shares of the biopharmaceutical company's stock after purchasing an additional 32,701 shares during the quarter. State Street Corp owned 0.37% of Xenon Pharmaceuticals worth $11,004,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of XENE. Blue Trust Inc. lifted its stake in Xenon Pharmaceuticals by 174.7% during the 3rd quarter. Blue Trust Inc. now owns 1,008 shares of the biopharmaceutical company's stock valued at $39,000 after acquiring an additional 641 shares during the period. nVerses Capital LLC acquired a new position in Xenon Pharmaceuticals during the third quarter valued at $102,000. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Xenon Pharmaceuticals by 21.6% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,740 shares of the biopharmaceutical company's stock valued at $106,000 after purchasing an additional 487 shares during the last quarter. Quarry LP boosted its holdings in Xenon Pharmaceuticals by 207.7% in the second quarter. Quarry LP now owns 4,000 shares of the biopharmaceutical company's stock valued at $156,000 after purchasing an additional 2,700 shares during the last quarter. Finally, XTX Topco Ltd acquired a new stake in Xenon Pharmaceuticals during the 2nd quarter worth about $464,000. Institutional investors and hedge funds own 95.45% of the company's stock.

Insider Activity at Xenon Pharmaceuticals

In other Xenon Pharmaceuticals news, CFO Sherry Aulin sold 18,709 shares of the firm's stock in a transaction on Wednesday, December 18th. The stock was sold at an average price of $41.21, for a total value of $770,997.89. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Gary Patou sold 4,891 shares of the business's stock in a transaction dated Friday, November 22nd. The shares were sold at an average price of $41.08, for a total transaction of $200,922.28. Following the transaction, the director now directly owns 23,573 shares in the company, valued at approximately $968,378.84. The trade was a 17.18 % decrease in their position. The disclosure for this sale can be found here. 5.52% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several equities analysts have recently issued reports on XENE shares. Needham & Company LLC reissued a "buy" rating and issued a $60.00 price objective on shares of Xenon Pharmaceuticals in a report on Wednesday, November 13th. Raymond James reissued an "outperform" rating and issued a $50.00 price target on shares of Xenon Pharmaceuticals in a report on Thursday, October 10th. William Blair raised shares of Xenon Pharmaceuticals to a "strong-buy" rating in a research note on Friday, August 30th. Royal Bank of Canada reiterated an "outperform" rating and issued a $55.00 target price on shares of Xenon Pharmaceuticals in a research note on Tuesday, September 3rd. Finally, HC Wainwright reissued a "buy" rating and set a $53.00 price target on shares of Xenon Pharmaceuticals in a report on Thursday, December 12th. Eight investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, the company has an average rating of "Buy" and a consensus price target of $56.00.

Xenon Pharmaceuticals Trading Up 2.8 %

NASDAQ:XENE traded up $1.06 during trading hours on Thursday, reaching $39.48. 241,548 shares of the company were exchanged, compared to its average volume of 389,904. The firm has a market cap of $3.01 billion, a PE ratio of -14.00 and a beta of 1.19. Xenon Pharmaceuticals Inc. has a twelve month low of $35.53 and a twelve month high of $50.99. The stock's 50-day moving average is $41.65 and its 200-day moving average is $40.49.

Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) last announced its earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.81) EPS for the quarter, beating analysts' consensus estimates of ($0.82) by $0.01. During the same period last year, the firm posted ($0.73) EPS. As a group, research analysts anticipate that Xenon Pharmaceuticals Inc. will post -3.1 EPS for the current year.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.